{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:36:53Z","timestamp":1790516213904,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014204","name":"Gateway Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.maturitas.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T18:52:35Z","timestamp":1581447155000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis"],"prefix":"10.1016","volume":"134","author":[{"given":"Margaret","family":"Rees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.maturitas.2020.01.005_bib0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.maturitas.2020.01.005_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: long-term health consequences","volume":"65","author":"Shuster","year":"2010","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.maturitas.2020.01.005_bib0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ecl.2015.05.003","article-title":"Surgical menopause","volume":"44","author":"Rodriguez","year":"2015","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Study of Women\u2019s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.maturitas.2018.01.012","article-title":"Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy","volume":"111","author":"Stuursma","year":"2018","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2016.05.011","article-title":"Hot flushes and night sweats symptom profiles over a 17-year period in mid-aged women: the role of hysterectomy with ovarian conservation","volume":"91","author":"Wilson","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0040","unstructured":"The National Institute for Health and Care Excellence. Menopause: diagnosis and management NICE guideline [NG23] Published date: November 2015 Last updated: December 2019 https:\/\/www.nice.org.uk\/guidance\/ng23. (Accessed 7 January 2020)."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.maturitas.2019.03.013","article-title":"EVES Study investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women","volume":"124","author":"Panay","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2018.02.005","article-title":"Hormone replacement therapy in cancer survivors: utopia?","volume":"124","author":"Angioli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.maturitas.2016.06.001","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"91","author":"de Villiers","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.maturitas.2016.04.013","article-title":"Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)","volume":"89","author":"Armeni","year":"2016","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.maturitas.2020.01.005_bib0065","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/GME.0000000000000319","article-title":"NAMS recommendations for clinical care of midlife women working group. The north american menopause society recommendations for clinical care of midlife women","volume":"21","author":"Shifren","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4158\/EP171828.PS","article-title":"AACE reproductive endocrinology scientific committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update","volume":"23","author":"Cobin","year":"2017","journal-title":"Endocr. Pract."},{"issue":"9","key":"10.1016\/j.maturitas.2020.01.005_bib0075","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/GME.0000000000001095","article-title":"Tissue selective estrogen complex (TSEC): a review","volume":"25","author":"Pickar","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0080","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2018.11.017","article-title":"Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation oftolerability and safety","volume":"121","author":"Di Donato","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.maturitas.2018.07.016","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase","volume":"116","author":"Sauer","year":"2018","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0095","unstructured":"Vagifem 10 micrograms vaginal tablets https:\/\/www.medicines.org.uk\/emc\/product\/5719\/smpc. (Accessed 7 January 2020)."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0100","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2017-01138","article-title":"Managing menopausal symptoms and associated clinical issues in breast Cancer survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.maturitas.2010.08.005","article-title":"Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions","volume":"67","author":"Desmarais","year":"2010","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JOP.18.00483","article-title":"Oral anticancer therapy: management of drug interactions","volume":"15","author":"Rogala","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0115","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1186\/s12885-016-2946-1","article-title":"Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors","volume":"16","author":"Atema","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.maturitas.2017.10.004","article-title":"Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide","volume":"107","author":"Cano","year":"2018","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0125","series-title":"Postmenopausal Diseases and Disorders","article-title":"Managing menopause and post-reproductive health: beyond hormones and medicines","author":"Marshall","year":"2019"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0130","article-title":"The associations between seven different types of physical activity and the incidence of fracture at seven sites in healthy postmenopausal UK women","author":"Armstrong","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0135","unstructured":"About Herbs, Botanicals & Other Products Memorial Sloan Kettering Cancer Center. https:\/\/www.mskcc.org\/cancer-care\/diagnosis-treatment\/symptom-management\/integrative-medicine\/herbs. (Accessed 7 January 2020)."},{"issue":"4","key":"10.1016\/j.maturitas.2020.01.005_bib0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Gynecologic Oncology Group Study.Randomized double\u2010blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0145","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ijgc-00009577-200603000-00054","article-title":"Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0150","first-page":"28","article-title":"Estrogen replacement therapy in patient with previous endometrial carcinoma","volume":"16","author":"Baker","year":"1990","journal-title":"Compr. Ther."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0155","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00007611-199006000-00044","article-title":"Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma","volume":"83","author":"Byrant","year":"1990","journal-title":"South. Med. J."},{"issue":"5","key":"10.1016\/j.maturitas.2020.01.005_bib0160","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stage I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.maturitas.2020.01.005_bib0165","first-page":"326","article-title":"Estrogen replacement therapy in the patient treated for endometrial cancer","volume":"67","author":"Creasman","year":"1986","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","article-title":"Estrogen replacement therapy following treatment for stage I endometrial carcinoma","volume":"36","author":"Lee","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2020.01.005_bib0175","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0180","unstructured":"Lynch syndrome UK. https:\/\/www.lynch-syndrome-uk.org\/womb. (Accessed 7 January 2020)."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0185","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0190","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines R). Uterine Neoplasms. NCCN Evidence Blocks TM Version 4.2019 \u2013 September 16, 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine_blocks.pdf. (Accessed 7 January 2020)."},{"issue":"9","key":"10.1016\/j.maturitas.2020.01.005_bib0195","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","article-title":"Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north Central Cancer treatment Group Trial N99C7","volume":"24","author":"Loprinzi","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.maturitas.2020.01.005_bib0200","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.2006.10.6179","article-title":"Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: southwest Oncology Group Study 9626","volume":"26","author":"Goodwin","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2020.01.005_bib0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2019.07.002","article-title":"Uterine smooth muscle tumors of unknown malignant potential: a challenging question","volume":"154","author":"Gadducci","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0210","unstructured":"ACS 2019 Cancer facts and figures https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2018\/cancer-facts-and-figures-special-section-ovarian-cancer-2018.pdf. (Accessed 7 January 2020)."},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0215","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2018.01.030","article-title":"Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US","volume":"149","author":"Liao","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.maturitas.2020.01.005_bib0220","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/ijc.24184","article-title":"Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact?","volume":"124","author":"Goodman","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.maturitas.2020.01.005_bib0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1055-9965.EPI-08-0771","article-title":"Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995\u20132004","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0230","series-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014"},{"issue":"1","key":"10.1016\/j.maturitas.2020.01.005_bib0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","article-title":"Histotype classification of ovarian carcinoma: a comparison of approaches","volume":"151","author":"Peres","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0240","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0245","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.maturitas.2020.01.005_bib0250","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0260","first-page":"192","article-title":"Hormone replacement therapy after epithelial ovarian cancer treatment","volume":"21","author":"Bebar","year":"2000","journal-title":"Eur. J. Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0265","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00042192-200101000-00012","article-title":"Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival","volume":"8","author":"Ursic-Vrscaj","year":"2001","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0270","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.maturitas.2020.01.005_bib0275","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/AOG.0000000000001396","article-title":"Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival","volume":"127","author":"Power","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"10","key":"10.1016\/j.maturitas.2020.01.005_bib0280","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpobgyn.2016.09.012","article-title":"Management of borderline ovarian tumours","volume":"41","author":"Gershenson","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.maturitas.2020.01.005_bib0290","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/13697137.2019.1582622","article-title":"Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines","volume":"22","author":"Vermeulen","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0295","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines R). Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN Evidence Blocks TM Version 3.2019 \u2013 November 26, 2019 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian_blocks.pdf. (Accessed 7 January 2020)."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.04.018","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers","volume":"116","author":"Rousset-Jablonski","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.maturitas.2020.01.005_bib0305","first-page":"1341","article-title":"Patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters","volume":"30","author":"Bodner","year":"2010","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.maturitas.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0090-8258(86)90134-4","article-title":"The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix","volume":"23","author":"Martin","year":"1986","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.maturitas.2016.07.018","article-title":"Menopausal hormone therapy in cancer survivors: a narrative review of the literature","volume":"92","author":"Kuhle","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0320","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2017.09.009","article-title":"Hormone replacement therapy after treatment for cervical cancer: are we adhering to standard of care?","volume":"147","author":"Rauh","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2020.01.005_bib0325","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.maturitas.2009.11.017","article-title":"Hormone replacement after gynaecological cancer","volume":"65","author":"Singh","year":"2010","journal-title":"Maturitas"},{"issue":"12","key":"10.1016\/j.maturitas.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clon.2016.08.016","article-title":"Iatrogenic menopause after treatment for cervical cancer","volume":"28","author":"Moss","year":"2016","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"1","key":"10.1016\/j.maturitas.2020.01.005_bib0340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/gyno.2000.5731","article-title":"Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix","volume":"77","author":"Lacey","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.maturitas.2020.01.005_bib0345","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","article-title":"Women\u2019s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Anderson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2020.01.005_bib0350","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.maturitas.2012.03.002","article-title":"Diethylstilboestrol--a long-term legacy","volume":"72","author":"Harris","year":"2012","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512220300256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512220300256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:15:58Z","timestamp":1759914958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512220300256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":70,"alternative-id":["S0378512220300256"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.01.005","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}